Bayer, Novartis, and Trump convicted by Nature
The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
Entries by Thomas Gabrielczyk
Drug from worms dampens autoimmune response
German researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model.
Fully digital partnering at BIO-Europe Spring 2020
BIO-Europe Spring: Leading life sciences partnering event pivots to deliver dealmaking
opportunities in a new format during very unusual times. With just 16 days to plan, EBD Group transformed BIO-Europe Spring from a physical event held in Paris to a fully digital solution where 1,700 delegates around the world participated in virtual partnering meetings and panels.
Life in a bubble – droplet science
It’s a discovery that revolutionises our fundamental understanding of cells. Tiny droplets called condensates that form through weak interactions between proteins and RNA are at the heart of many key biological processes. Dewpoint Therapeutics – the first start-up to harness the basic research for a new therapeutic platform technology – is now opening a facility in the German capital Berlin.
Nanolitre dispensing
The acoustic dispensing technology of the Echo-Series Liquid Handlers has revolutionised the transfer of liquids.
Swiss biotech sector with robust growth
Last year, the biotechnology sector in Switzerland has continued its growth and proved to be a magnet for fresh capital and investment. This is revealed by the Swiss Biotech Report 2020.
Viral vector one-stop-shop for gene and cell therapy
Many CDMOs have taken actions to meet the growing demand of viral vector development and manufacturing services for clinical trials, as well as for commercial scale production. While capacity is important, there are only a few companies who provide services across the entire supply and value chain. So, what should you expect when choosing a true one-stop-shop as a CDMO partner in the gene therapy space?
COVID-19: Novartis starts study on hyped malaria drug
Up to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.
COVID 19: Halix ready for vaccine production
Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .
Carbios SAS publishes PET recycling technology
For years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.